Kornimate/medical-research-clean huggingface dataset:
a prediction model and assisted decision-making system of fertilization disorders

Conditions: Infertility

Summary: the goal of this clinical trial is to test the accuracy of the forecasting system we develop. the main question it aims to answer is: * whether the clinical prediction system predicts the incidence of fertilization disorders accurately. * the fertilization disorder prediction system predicts whether and how much the outcome differs from the doctor. participants will receive treatment assisted by a predictive system or receive general treatment. researchers will compare incidence of fertilization disorders to see if the fertilization disorder prediction system makes correct predictions.

through the design method of single-center randomized controlled trial, 260 infertility patients were recruited, and they were divided into two groups of 130 cases in each group according to the method of block randomization, one of which was the intervention group, with the help of accurate prediction of fertilization disorders and clinical decision support systems, clinicians predicted and judged the probability and key factors of fertilization disorders of patients, and formulated and implemented personalized diagnosis and treatment plans based on the prediction results; the other group is the control group, which is treated by clinicians according to the conventional diagnosis and treatment plan, and the system performs parallel simulation operation to predict the outcome of fertilization disorders in patients without affecting any diagnosis and treatment decisions of clinicians. through the comparison of the two groups, the predictive ability of the system for fertilization disorders was evaluated, and the effectiveness and safety of the personalized diagnosis and treatment plan formulated with the assistance of the system were observed, the primary observation outcomes were the incidence of fertilization disorders, and the secondary observation outcomes were embryo transfer rate, biochemical pregnancy rate, clinical pregnancy rate, etc.

Eligibility criteria:
inclusion criteria: 1. infertile couples 2. have indications for acceptance of ivf or icsi 3. both parties sign an informed consent form and can complete the follow-up visit exclusion criteria: 1. at least one of the spouses has contraindics to ivf or icsi 2. major diseases 3. fresh cycle, pgt, ivm
erlotinib versus carboplatin/vinorelbine in elderly patients with advanced non-small cell lung cancer (nsclc)

Conditions: Non-Small Cell Lung Cancer

Summary: 60% of all malignant diseases occur in patients who are 65 years or older. for these patients, aggressive treatments are often not suitable due to reduced life-expectancy, reduced general condition, comorbidities, and reduced vital functions which can lead to increased adverse effects of chemotherapy. therefore, it is important to investigate alternative therapy options for elderly patients. erlotinib is an orally applied medication which is associated with reasonable toxicity. this targeted agent may prove an effective and well-tolerated first-line therapy in elderly patients with advanced non small cell lung cancer. therefore, the aim of this study is to investigate the progression-free survival of the combination of vinorelbine and carboplatin in comparison to erlotinib. given that there will be no significant reduction of efficiency this may provide elderly patients of more than 70 years of age with an active oral substance without subjecting them to the sometimes severe adverse effect of the chemotherapy.


Eligibility criteria:
inclusion criteria: * histologically or cytological proven nsclc, stage lll b (with pleural effusion) or stage lv. * tumour is locally advanced and not suitable for surgery and radiotherapy is not indicated. * neither cytostatic nor immunological pre-treatment * age \>70 years * at least one measurable lesion (recist criteria) that was not previously irradiated * ecog performance status 0-1 * life expectancy \> 3 month * adequate bone marrow function: anc \> 1.5 x 109/l, platelets \> 100 x 109/l * adequate liver function: total bilirubin \< 1.5 x uln, got/gpt\< 3 x uln (existent liver metastases \< 5 x uln) * adequate renal function:creatinine clearance \> 45 ml/min (calculated according to cockroft-gault) * fertile men must agree to use an effective method of birth control while participating in this study * signed written informed consent exclusion criteria: * uncontrolled metastasis in the cns * acute, heavy uncontrolled infection * any other serious concomitant disease or medical condition, which could interfere with participating in this study * severe hypersensitivity to erlotinib or any other component * hypersensitivity to carboplatin and/or other platinum compounds * hypersensitivity to vinorelbin or other vinca-alkaloids * patients with a history of other active malignancy in the past 5 years (with the exception of carcinoma in situ of the cervix, non melanomatous skin cancers or local prostate carcinoma that was surgically treated successfully) are excluded. * participation in another clinical trial with any investigational drug at the same time or within 30 days prior to registration * psychological, familial, social or geographical situations limiting the compliance with the study requirements

Keywords: nsclc elderly patients
safety, tolerability and pharmacodynamics of ap214 acetate in patients undergoing cardiac surgery

Conditions: Cardiac Surgery; Coronary Artery Bypass Grafting; Valve Surgery; Kidney Injury

Summary: the purpose of the present research study is to investigate for the first time, the safety and tolerability of infusion doses of ap214 in subjects having heart surgery such as coronary bypass graft and/or valve repair or replacement surgery. ap214, the investigational drug, is being developed to potentially prevent post-surgical kidney injury after thoracic aortic aneurysm repair.


Eligibility criteria:
inclusion criteria: 1. has signed the trial specific informed consent form. 2. patients ≥ 18 years old, male or female, not of childbearing potential (postmenopausal or permanently sterilized e.g., tubal occlusion, hysterectomy, bilateral salpingectomy), regardless of ethnicity. 3. patients undergoing cabg, valve(s), cabg/valve and/or aortic root or ascending aortic aneurysm repair surgery. 4. cleveland clinic renal score ≥ 2 (higher than average risk for aki). 5. ef ≥ 30%, evaluated within 2 months prior to screening visit. exclusion criteria: 1. cardiac surgery to be performed "off pump" without cardiopulmonary bypass. 2. circulatory arrest in connection with aortic root or ascending aortic aneurysm repair surgery. 3. confirmed or suspected endocarditis. 4. requiring a reoperation on one of the valves within 3 months following the original valve surgical procedure. 5. receiving aprotinin during the trial, from screening to day 90. 6. having undergone cardiovascular catheterization ≤ 48 hours prior to scheduled surgery. 7. active peptic ulcer disease and gastritis. 8. hemoccult positive stools, hematological, bleeding, and coagulation disorders. 9. receiving dopamine at renal doses (2-4 mcg/kg/min), from screening to day 90. 10. s-creatinine greater than 2.1 mg/dl. 11. known or suspected hypersensitivity to the investigational medicinal product. 12. known or suspected hypersensitivity to ondansetron or other selective 5-hydroxytryptamine 3 (5-ht3) receptor antagonists. 13. current participation in any other interventional clinical trial. 14. previously dosed with ap214. 15. use of investigational medicinal products within the previous 6 months. 16. body weight above 140 kg. 17. history of any organ transplant. 18. women who are of childbearing potential, pregnant or breast-feeding. 19. current abuse of alcohol or substance, according to the investigator's medical judgment 20. has a mental incapacity or language barriers precluding adequate understanding of trial procedures. 21. is considered by the investigator unsuitable to participate in the trial for any other reason for instance due to a significant serious underlying condition

Keywords: cardiac surgery coronary artery bypass grafting valve surgery acute kidney injury
clinical performance of a glass-ionomer restorative system in extended-sized cavities

Conditions: Dental Caries Class II

Summary: the aim of this clinical trial was to compare the clinical performances of a glass ionomer restorative system with a micro hybrid resin based composite in extended sized class ii cavities. a total of 100 class 2 lesions were restored with a glass ionomer restorative system (equia forte) or a micro hybrid composite (g-aenial posterior). restorations were evaluated at baseline and yearly during 6 years according to the modified-usphs criteria. data were analyzed with cohcran's q and mcnemar's tests (p\<0.05).

since the introduction of glass ionomers many modifications of these materials have been performed over the years. compared to other permanent filling materials like resin-based composites, glass ionomers show several advantages, such as the ability to adhere to moist enamel and dentin and anti-cariogenic properties such as the long-term fluoride release. so, it was doubtful that glass ionomers represent a capable counterpart of amalgam or resin-based composites in posterior teeth.

Eligibility criteria:
inclusion criteria: 1. a need for at least two but not more than four posterior toothcolored restorations; 2. the presence of teeth to be restored in occlusion; 3. teeth that were symptomless and vital; 4. a normal periodontal status; 5. a good likelihood of recall availability. exclusion criteria: 1. partly erupted teeth; 2. absence of adjacent and antagonist teeth 3. poor periodontal status; 4. adverse medical history; 5. potential behavioral problems.

Keywords: glass ionomer cement composite resin
is reflexology applied to children with cerebral palsy an effective method?

Conditions: Cerebral Palsy; Reflexology

Summary: objectives: this study was planned to investigate the influence of reflexology applied to children with cerebral palsy together with physical therapy program involving neurodevelopmental approaches. methods: the study involved 40 children aged,16 girls and 24 boys between 3 and 15 years and divided into two groups. while the children in group 1 were given twice a week for eight weeks neurodevelopmental treatment, reflexology was applied to those in group 2 together with neurodevelopmental treatment. drooling severity and frequency scale, pediatric sleep questionnaire and the children's health questionnaire was used to assess the drooling, status of sleep and quality of life in children.

the study involved a total of 40 children aged between three and 15 diagnosed with cp by a pediatric neurologist. children at levels 3/4/5 of the gmfcs who did not have any open wounds on the foot, where the application was to be performed, and whose parents consented to the child's participation were accepted in the study. however, those children were excluded who were treated with botulinum toxin in the last six months, underwent surgery, were treated with reflexology or any other alternative medicine method and who had refractory epilepsy.

Eligibility criteria:
inclusion criteria: * children at levels 3/4/5 of the gmfcs who did not have any open wounds on the foot, where the application was to be performed, and whose parents consented to the child's participation were accepted in the study. exclusion criteria: * who were treated with botulinum toxin in the last six months, underwent surgery, were treated with reflexology or any other alternative medicine method and who had refractory epilepsy.
feasibility study for electroacupuncture for chemotherapy- induced peripheral neuropathy (cipn)

Conditions: Chemotherapy-induced Peripheral Neuropathy

Summary: the purpose of the study is to determine the validity of a point-of-care nerve conduction device (neurometrix) and rydel-seiffer tuning fork in assessing the level of peripheral neuropathy in patients with chemotherapy-induced peripheral neuropathy (cipn). chemotherapy-induced peripheral neuropathy (cipn) is a common, persistent toxicity among patients who receive chemotherapy. it is characterized by a variety of sensory and motor symptoms such as numbness, tingling, reduced sense of touch, reduced proprioception (awareness of your limb and body position in space), pain, weakness, balance disturbances, and deficits in motor skills.


Eligibility criteria:
inclusion criteria: * must have undergone chemotherapy with taxane and/or platinum agent * presence of numbness, paresthesias, loss of deep tendon reflexes, or other symptoms in the lower extremities those were absent prior to treatment with neurotoxic chemotherapy. * three or more months status post platinum containing chemotherapy completion * grade ≥1 level of cipn that is determined by the nci common toxicity criteria for adverse events. exclusion criteria: * peripheral neuropathy from causes other than chemotherapy, such as documented * a. nerve compression (carpal tunnel syndrome, sciatica, etc) * b. previously known leptomeningeal carcinomatosis * c. evidence of disease in the brain or spine by prior imaging * comorbidities with documented pre-existing neuropathy prior to the chemotherapy such as * a. diabetes (hba1c 6.5% or greater) * b. hiv * c. multiple myeloma * d. alcoholism * pain medication dosing, including opioids, anti-convulsants, and anti- depressantshas been increased due to worsening symptoms less than in the two weeks prior to study registration * current use of acupuncture (manual or electro acupuncture) * pregnancy * cardiac issues (aha class 3 or greater) * pacemaker or an imbedded neural stimulator * full therapeutic anticoagulation or a inr \> 1.4 * currently undergoing chemotherapy with a platinum agent or have received a platinum chemotherapy agent in the past 3 months.

Keywords: numbness pain tingling reduced sense of touch reduced proprioception sensory neuropathy
impact of adult asthma

Conditions: Asthma; Lung Diseases

Summary: to assess the separate and interactive effects of asthma severity, subspecialty practice variation, asthma-related psychosocial variables, and other factors on asthma outcomes, including asthma-specific quality of life and activity limitations, health care utilization for asthma, and direct and indirect costs of asthma.

background: asthma is both common and costly. neither the risk factors of poor outcome nor the predictors of better outcome are well understood. illness severity is clearly an important predictive factor in asthma, but may explain less variability in outcome than other determinants, such as patient-perceived asthma control, other asthma-related psychosocial measures, and the kind and extent of subspecialty care for asthma. by quantifying predictors of asthma-specific quality of life, functional status, services utilization, and the direct and indirect illness costs of asthma, this study addressed a major research gap in secondary and tertiary prevention efforts. design narrative: a random sample of pulmonary and allergy subspecialists initially enrolled 600 persons with asthma identified in patient visit logs. this established panel completed 45 minute baseline and follow-up computer-assisted telephone interviews (cati); 539 (90%) were successfully re-interviewed after 18 months of follow-up. a supplemental sampling frame of persons with asthma identified from family practitioners was completed as was a group with rhinitis but without asthma. interviews assessed disease severity and other covariables using validated survey instruments. pulmonary function and medical records were used to validate severity in a sub-sample of subjects. the study extended longitudinal follow-up study of this initial cohort. its analysis tested predictive models for the asthma outcomes of interest. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
an ocd prevention programme for at risk adults

Conditions: Obsessive-Compulsive Disorder

Summary: the main purpose of this randomised clinical trial is to test the efficacy of a prevention program for adult who are at risk of developing ocd, thus constituting a form of tertiary prevention.

after being informed about the study and giving written informed consent, all eligible participants will be randomised into the experimental group or the control group (tau). participants will be blind to the group allocation. the experimental group will undergo a two weeks ocd prevention program, consisting of three group sessions per week. the control group will not receive any intervention. researchers will compare the experimental group to the control group to test wether the prevention programme is efficient in reducing ocd symptomatology.

Eligibility criteria:
inclusion criteria: - age over 18 exclusion criteria: * clinically diagnosed ocd * current psychiatric/psychotherapeutic treatment * personality disorder diagnosis * suicidal ideation

Keywords: risk prevention
adaptive behavior assessment of men with 49, xxxxy, klinefelter syndrome

Conditions: Klinefelter Syndrome

Summary: klinefelter syndrome, a congenital chromosomal abnormality with one or more extra x chromosomes, occurs in out of 400 live male births. the majority of klinefelter men present with a 47, xxy karyotype. the "poly-x variant", with the 49,xxxxy karyotype is uncommon. this syndrome, where subjects have two or more x chromosomes presents with primary hypogonadism, and, particularly if associated with the 49,xxxxy karyotype, significantly impacts life skills across a variety of dimensions, including areas of communication, community use, functional academics, home/school living, health and safety, leisure, self-care, self direction, and work. adaptive behavior abnormalities in 46,xxy men are well known and described. in the poly-x variant of the 49,xxxxy karyotype, adaptive behavior abnormalities are expected to be much more significant, making these patients eligible for services and social security benefits. in 49,xxxxy men no study to date has examined these areas of inquiry in a large patient population, using a psychometrically sound instrument in a large patient population. current publications are limited to individual case reports or small case summaries. it is important to study the adaptive behavior in its highly abnormal presentation in 49,xxxxy men in order to learn more about the effect of additional x chromosomes on adaptive skills, which determine how an individual responds to daily demands and in order to develop treatment and training goals.


Eligibility criteria:
inclusion criteria: * any klinefelter male with proven 49,xxxxy karyotype, who does not present with and is not being treated for significant physical/mental illness which might affect his adaptive behavior, who or whose parent or primary caretaker is able to provide informed consent to participate in the study and who or whose parent or primary caretaker has adequate command of the english language, to provide meaningful information will be invited to participate in this study.

Keywords: kleinfelter
heart pathway implementation

Conditions: Chest Pain; Acute Coronary Syndrome; Chest Pain Atypical Syndrome; Chest Pain Rule Out Myocardial Infarction

Summary: the purpose of this study is to determine the effectiveness of the heart pathway, a clinical decision aid for the care of patients with chest pain, in a "real-world" clinical setting. this will be accomplished through the building of a transformative collaboration between research, education, and health systems operations to more effectively and efficiently provide patient care.

millions of patients with chest pain are seen in emergency departments (eds) every year. over half of ed patients with chest pain are admitted to the hospital to undergo further testing. despite high testing rates, less than 1 in 10 patients with chest pain are ultimately diagnosed with an acute coronary syndrome (acs) at estimated annual cost of $13 billion. current care patterns for acute chest pain fail to focus health system resources, such as hospitalization and cardiac testing, on patients most likely to benefit. the heart pathway, which combines a clinical decision aid, with two serial troponin measurements, has been developed to identify patients with chest pain who can safely be discharged without objective cardiac testing (stress testing or angiography). prior retrospective and observational studies have established that use of the heart pathway reduces cardiac testing by \>20%, while maintaining an acceptably low adverse event rate. we now seek to integrate the heart pathway into "real-world" clinical settings to determine effectiveness. the goal of this proposal is to build a transformative collaboration bridging the gap between research, education, and health systems operations to more effectively and efficiently provide patient care. the vanguard for this collaboration seeks to improve quality of care for patients with acute chest pain by integrating the heart pathway into cardiovascular care delivery at wake forest baptist health (wfbh). this project will build on our prior work and provide a model for using the education and operational strengths of us academic medical centers to disseminate initiatives to improve care delivery.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 21 years of age at the time of emergency department (ed) visit * chest discomfort consistent with possible acute coronary syndrome (acs) as indicated by the treating physician obtaining an electrocardiogram (ecg) and cardiac biomarkers for the patient's evaluation. exclusion criteria: * new st-segment elevation in contiguous leads on any electrocardiogram (\>/= 1 mv)

Keywords: acute coronary syndrome chest pain risk stratification clinical decision aid emergency department low risk chest pain non cardiac chest pain
evaluation of metal-on-conventional-polyethylene vs ceramic-on-ceramic articulating surfaces in total hip arthroplasty

Conditions: Arthroplasty Complications

Summary: polyethylene wear debris from metal-on-polyethylene articulations are one of the main causes of periprosthetic bone loss and non-infectious loosening in total hip arthroplasty. ceramic articulations have a very low wear rate when measured in the laboratory and the investigator's hypothesis is that hip arthroplasty with an all ceramic articulation will have less osteolysis and wear in addition to equally good fixation and clinical outcome compared to the same hip arthroplasty design with a metal-on-polyethylene joint.


Eligibility criteria:
inclusion criteria: * primary osteoarthritis * secondary osteoarthritis caused by idiopathic osteonecrosis, dysplasia or childhood disease (mb perthes, epiphysiolysis) exclusion criteria: * inflammatory arthritis * hip joint infection

Keywords: biomaterials implant wear hip arthroplasty osteolysis aseptic loosening
the use of residual de-identified specimens and/or samples from patients for clinical research

Conditions: Hematologic Diseases

Summary: acquire residual human specimens and/or samples from patient samples which were sent for testing at labpmm, llc for clinical research

residual specimen/sample collection study where peripheral blood (pb), bone marrow (bm), genomic (gdna), and/or formalin-fixed paraffin-embedded tissue (ffpe) specimens/samples are obtained from patient samples sent to labpmm, llc for clinical testing. samples may be used for clinical research at labpmm, llc or at partner institutions

Eligibility criteria:
inclusion criteria: 1. specimen/sample, peripheral blood (pb), bone marrow (bm), genomic dna (gdna) and/or formalin-fixed paraffin-embedded tissue (ffpe) from patients whose specimens/samples have been sent to labpmm for clinical testing 2. donor age ≥ 18 years exclusion criteria: 1. sample/specimen has been obtained from a third-party vendor with a materials transfer agreement (mta) on file with labpmm 2. the specimens/samples have previously been enrolled in a clinical study

Keywords: residual samples hematologic diseases